^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ALPL (Alkaline Phosphatase)

i
Other names: ALPL, Alkaline Phosphatase, Biomineralization Associated, TNSALP, TNALP, TNAP, Alkaline Phosphatase, Tissue-Nonspecific Isozyme, Alkaline Phosphatase Liver/Bone/Kidney Isozyme, Tissue Non-Specific Alkaline Phosphatase, Alkaline Phosphatase, Liver/Bone/Kidney, Phosphocreatine Phosphatase, Phosphoamidase, AP-TNAP, TNS-ALP, HOPS, Liver/Bone/Kidney-Type Alkaline Phosphatase, Tissue-Nonspecific ALP, APTNAP, HPPA, HPPC, HPPI, HPPO
Associations
6d
pH-Responsive Nanoparticle-Coated Calcium Phosphate Granules for Bone Cancer Therapy. (PubMed, Small)
In this study, we develop β-tricalcium phosphate (β-TCP) granules decorated with selenium (Se)-doped mesoporous silica nanoparticles (SeMIA@TCP), in which nanoparticles are functionalized with imine bonds for acidic pH-responsive detachment and alendronate for strong β-TCP binding...Furthermore, the released nanoparticles enhanced alkaline phosphatase (ALP) expression and mineralization in hMSCs, underscoring their osteogenic potential. Collectively, these results demonstrate the potential of tumor microenvironment-responsive Se-doped MSN-assembled TCP granules as a design platform for bifunctional scaffolds in bone cancer treatment.
Journal
|
ALPL (Alkaline Phosphatase)
18d
New trial
|
ALPL (Alkaline Phosphatase)
2ms
Truncated FOS impairs osteogenic differentiation and induces prostaglandin and NFκB signalling in an in vitro cell-of-origin model for osteoid osteoma and osteoblastoma. (PubMed, J Pathol)
© 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
Preclinical • Journal
|
ALPL (Alkaline Phosphatase)
3ms
Clinical Retrospective Study on the Role of Spleen-Invigorating and Qi-Supporting Therapy in Non-Small Cell Lung Cancer Immunotherapy and Construction of Survival Prediction Model. (PubMed, Biol Proced Online)
The addition of TCM to PD‑1/PD‑L1 inhibitors prolongs PFS and OS in patients with stage IIIB-IV NSCLC. A survival prediction model based on routine clinical characteristics demonstrates predictive utility, offering a potential tool to inform clinical decision‑making.
Retrospective data • Journal • IO biomarker
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • ALPL (Alkaline Phosphatase)
|
PD-L1 expression
3ms
Trial completion date
|
ALPL (Alkaline Phosphatase)
4ms
Imbalance of Serum Bone-Metabolism-Related Factors Associated with Osteonecrosis of the Jaw. (PubMed, Biomedicines)
In addition, a significant decrease in the expression of alkaline phosphatase liver/bone/kidney (p < 0.05, effect size of 0.46 (95% CI: 0.08 to 0.73)) and a significant increase (p < 0.05, effect size was -0.42 (95%CI: -0.72 to 0.01)) in the expression of tumor necrosis factor α were observed in the MRONJ group. These results may contribute to a better understanding of the etiology, pathophysiology, and progression of MRONJ.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ALPL (Alkaline Phosphatase)
|
Prolia (denosumab)
4ms
Alkaline phosphatase (ALPL) as a diagnostic and prognostic biomarker linked to immune response in thyroid cancer. (PubMed, Gland Surg)
ALPL is a key biomarker in THCA, driving tumor progression and poor outcomes through its roles in proliferation, invasion, and immune modulation. These findings support its potential as a diagnostic and prognostic marker.
Journal
|
ALPL (Alkaline Phosphatase)
4ms
Membrane Palmitoylated Protein 7 is Required for Osteogenesis and is Linked with Bone Mineralization and Osteoporosis: The Functional Evaluation of GEFOS GWAS Hit. (PubMed, Calcif Tissue Int)
Knockout cells also displayed altered morphology, suggesting that MPP7 influences osteoblast function via effects on cell polarity and adhesion. Collectively, our findings, together with zebrafish genetic evidence, indicate that MPP7 plays a critical role in osteoblast differentiation and mineralization and may contribute to osteoporosis susceptibility in humans.
Journal
|
ALPL (Alkaline Phosphatase)
5ms
ALPHA-TOCOPHEROL AND G-CSF CHANGE EXPRESSION OF GENES ASSOCIATED WITH DIFFERENTIATION OF K562 CHRONIC MYELOID LEUKEMIA CELLS DOWNREGULATING EMT-ASSOCIATED STEMNESS BIOMARKERS. (PubMed, Exp Oncol)
The inverse relationship between expression of the genes of leukemic stemness cell markers SNAIL, OCT4, and PLAP and the genes of myeloid differentiation markers C/EBPα, TNAP, and E-cadherin in K562 cells exposed to alpha-tocopherol or G-CSF suggests the activation of the molecular pattern of myeloid differentiation in this setting.
Journal
|
CDH1 (Cadherin 1) • ALPP (Alkaline Phosphatase, Placental) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • POU5F1 (POU Class 5 Homeobox 1) • SNAI1 (Snail Family Transcriptional Repressor 1) • ALPL (Alkaline Phosphatase)
5ms
Registry of Patients With Hypophosphatasia (clinicaltrials.gov)
P=N/A, N=1571, Enrolling by invitation, Alexion Pharmaceuticals, Inc. | N=900 --> 1571
Enrollment change
|
ALPL (Alkaline Phosphatase)
6ms
A Prospective Sub-Study of the Global Hypophosphatasia Registry (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Alexion Pharmaceuticals, Inc. | Trial completion date: Aug 2029 --> Jul 2028 | Trial primary completion date: Aug 2029 --> Jul 2028
Trial completion date • Trial primary completion date
|
ALPL (Alkaline Phosphatase)
6ms
MULBERRY: Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (clinicaltrials.gov)
P3, N=30, Active, not recruiting, Alexion Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
ALPL (Alkaline Phosphatase)